Chemomab Therapeutics annual capital expenditures (capex)
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Capital Expenditures (CapEx) Growth & History (CMMB)
Chemomab Therapeutics's capital expenditures (capex) was $3,000 for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3,000 | $3,000 | — |
| 2024 | 2024-12-31 | $0 | −$3,000 | — |
| 2023 | 2023-12-31 | $3,000 | −$65,000 | −95.59% |
| 2022 | 2022-12-31 | $68,000 | −$171,000 | −71.55% |
| 2021 | 2021-12-31 | $239,000 | $201,000 | +528.95% |
| 2020 | 2020-12-31 | $38,000 | −$57,000 | −60.00% |
| 2019 | 2019-12-31 | $95,000 | −$118,000 | −55.40% |
| 2018 | 2018-12-31 | $213,000 | $179,000 | +526.47% |
| 2017 | 2017-12-31 | $34,000 | −$41,000 | −54.67% |
| 2016 | 2016-12-31 | $75,000 | — | — |
Chemomab Therapeutics quarterly capital expenditures (capex)
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2023 | 2023-06-30 | $2,000 | −$9,000 | −81.82% |
| Q1 2023 | 2023-03-31 | $1,000 | −$13,000 | −92.86% |
| Q4 2022 | 2022-12-31 | $1,000 | −$133,000 | −99.25% |
| Q3 2022 | 2022-09-30 | $42,000 | $42,000 | — |
| Q2 2022 | 2022-06-30 | $11,000 | −$91,000 | −89.22% |
| Q1 2022 | 2022-03-31 | $14,000 | $11,000 | +366.67% |
| Q4 2021 | 2021-12-31 | $134,000 | $133,000 | +13300.00% |
| Q3 2021 | 2021-09-30 | $0 | −$20,000 | — |
| Q2 2021 | 2021-06-30 | $102,000 | $95,000 | +1357.14% |
| Q1 2021 | 2021-03-31 | $3,000 | −$7,000 | −70.00% |
| Q4 2020 | 2020-12-31 | $1,000 | −$250,000 | −99.60% |
| Q3 2020 | 2020-09-30 | $20,000 | −$235,000 | −92.16% |
| Q2 2020 | 2020-06-30 | $7,000 | −$9,000 | −56.25% |
| Q1 2020 | 2020-03-31 | $10,000 | −$65,000 | −86.67% |
| Q4 2019 | 2019-12-31 | $251,000 | — | — |
| Q3 2019 | 2019-09-30 | $255,000 | — | — |
| Q2 2019 | 2019-06-30 | $16,000 | — | — |
| Q1 2019 | 2019-03-31 | $75,000 | — | — |
Chemomab Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Chemomab Therapeutics's capital expenditures (capex) decreased from $38,000 to $3,000, a change of −$35,000. The latest reported quarter, Q2 2023, shows $2,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗